Atypical Haemolytic Uraemic Syndrome (aHUS)
Atypical Haemolytic Uraemic Syndrome (aHUS) is characterised by systemic thrombotic microangiopathy (TMA). TMA is a pathology that results in thrombosis in capillaries and arterioles due to an endothelial injury. It may be seen in association with thrombocytopenia, anemia, purpura and renal failure.
aHUS is an extremely rare, life threatening and progressive disease that frequently has a genetic component. In most cases it is caused by chronis uncontrolled activation of the complement system.
The National aHUS Service was established in England following the NICE guideline on the use of Eculizumab for aHUS. The Coagulation laboratory diagnostics service in Newcastle upon Tyne Hospitals. The aHUS service encompasses a comprehensive genetic and immunological evaluation of the complement system to facilitate diagnoses of aHUS and exclusion of TTP.
|Min. Volume:||The volume of blood in coagulation samples must lie within the volume range as indicated by the size of the black fill arrow present on tubes. Volumes above or below the arrow will result in sample rejection to ensure validity of results.|
|Turnaround Time:||4 hours|
|Age of Sample:||Samples will be rejected if received more than 1 hours post venepuncture.|
Following blood draw it is essential to deliver samples to the Coagulation laboratory within 15 minutes for processing
|Analysing Laboratory:||National aHUS service at the Royal Victoria Infirmary in Newcastle.|